On 19 December 2016, the European Medicines Agency (“EMA”) published an updated version of the EMA guidance document concerning post-authorisation procedural advice for users of ...24 January 2017
CMS Proposes New Standards for Medicaid and CHIP Income Eligibility
Starting January 1, 2014, for most individuals, eligibility for Medicaid and CHIP will be determined using methodologies based on MAGI, as defined by the Internal Revenue Code of 1986. Moreover, aside from a five-percent across-the-board income disregard, there will no longer be any applicable income disregards. CMS issued regulations regarding these new income eligibility standards on March 27, 2012. As required by PPACA, these standards will not apply to certain exempted populations, whose eligibility will continue to be determined using current income eligibility standards.
To effectuate these changes, section 2002 of PPACA requires states to convert their current financial eligibility income standards from net standards that incorporate current income disregards to an equivalent MAGI income standard. States must further ensure that this “income conversion” does not render individuals eligible for Medicaid on the date of PPACA’s enactment ineligible for Medicaid coverage. In its solicitation for public input, CMS sets forth two potential methodologies for implementing these requirements: (1) the average disregard/major average disregard method; and (2) the same number net and gross method. Both of these methods aim to ensure that the same number of individuals is eligible for Medicaid, although not necessarily the same exact individuals.
CMS solicits comments from interested stakeholders regarding the feasibility of these two options as well as with respect to hybrid or alternative methodologies. Comments may be submitted electronically to email@example.com and should be submitted by July 23, 2012.
Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (“the Clinical Trials Regulation”) was...24 January 2017
The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has published a draft strategy for developing pharmacopoeial public quality standards for biological...20 January 2017